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INTRODUCTION: 
Despite considerable advances made in the field of 
medicine in general, and nephrology in particular, 
Chronic Kidney Disease (CKD) and End Stage Renal 
Disease (ESRD) remains a public health challenge of 
enormous proportion1. Studies have found that 
cardiovascular diseases are a leading cause of mortality 
for ESRD patients2. Cardiac mortality in dialysis patients 
is more than 10-fold greater than that of the general 
population2. Of late, Insulin Resistance (IR) has been 
implicated as the underlying cause of a constellation of 
cardiovascular symptoms3. IR is common in patients 
with mild-to-moderate CKD4. Insulin resistance is also 
an independent predictor of cardiovascular mortality in 
End Stage Renal Disease5  (ESRD) and is increasingly 
recognized as a nontraditional risk factor6, 7.  
Considering that the association between Insulin 
resistance and CKD and ESRD has been established in 
studies conducted abroad, we propose to verify the 
association in Indian setting i.e. among ESRD patients in 
eastern India.  
MATERIALS AND METHODS: 
Patients were recruited from outpatient department of a 
reputed healthcare delivery centre in eastern India. This 
study was performed in accordance with the relevant 
ethical guidelines. Only patients/subjects providing 
written consent after being explained the study protocol 
were included in the study. 95 patients were included in 
control group and 97 patients were included in ESRD 
group. The following selection criteria were used for 
patient recruitment: 
Inclusion criteria: 
ESRD patients of either sex and their age and sex 
matched controls, who attended the OPDs during the 
study period and gave their voluntary written informed 
consent for the study. 
Exclusion Criteria: 
1. Obese patients 
2. Diabetic patient 
3. Metabolic syndrome patients 
4. Endocrinopathy patients 
5. Nephrotic syndrome 
6. Pregnant and lactating mothers 
7. Patients suffering from malignancy and terminally ill 
patients 
8. Patients who are on drugs, known to cause Insulin 
resistance (e.g. Corticosteroids, Olanzapine etc) 
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Normal renal function was defined according to the 
National Kidney Foundation Kidney Disease Outcome 
Quality Initiative (K/DOQI) definitions [estimated 
glomerular filtration rate (GFR) > 120 ml/min per 
1.73m2]. Patients with GFR less than 15 ml/min per 
1.73m2 were included in ESRD group. GFR was 
calculated using MDRD formula. 
None of the ESRD patients was on hemodialysis or 
peritoneal dialysis. 
Study Protocol: 
Before collection of data or blood sample, each patient 
was explained the details of the study including rationale, 
expected benefits, risk profile, confidentiality safeguards 
and study protocol. For some patients, help of 
appropriate interpreter(s) was taken. Only those patients 
who were willing to follow the study protocol and gave 
their written consent were included in the study. There 
was neither any financial cost nor any financial incentive 
for the patient for being part of the study. 
1. Appropriate blood samples were collected from 
ESRD patients. For estimation of serum Insulin (Ins) 
level, serum high sensitive CRP (hsCRP) level, 
serum Cholesterol (Cho) level, serum Triglyceride 
(Tgl), serum High Density Lipoprotein (HDL) level, 
serum Low Density Lipoprotein (LDL) level, fasting 
blood sample was drawn into serum (without 
anticoagulant) gel containing yellow colour capped 
BD Vacutainer tubes. For plasma Glucose (Glu) 
level, blood sample were drawn into fluoride-oxalate 
anticoagulant containing gray colour capped BD 
Vacutainer tubes. All samples were immediately 
centrifuged, separated and stored at 2-8oC until 
analysis for the relevant biochemical parameters. 
2. Plasma Glucose was measured by Dimension RXL 
Max autoanalyzer using Hexokinase principle. 
3. Serum hsCRP was measured by Dimension RXL 
Max autoanalyzer instrument using 
immunoturbidimetric principle. 
4. Serum Urea was measured by Dimension RXL Max 
autoanalyzer instrument using Urease principle. 
5. Serum Creatinine was measured by Dimension RXL 
Max autoanalyzer instrument using Alkaline Picrate 
Kinetic principle. 
6. Serum Triglyceride was measured by Dimension 
RXL Max autoanalyzer instrument using GPO-
POD-AAP principle. 
7. Serum Cholesterol was measured by Dimension 
RXL Max autoanalyzer instrument using CE-
CHOD-AAP principle. 
8. Serum HDL was measured by Dimension RXL Max 
autoanalyzer instrument using AHDL method. 
9. Serum LDL was measured by Dimension RXL Max 
autoanalyzer instrument using ALDL method. 
10. Serum Ins was measured by Abbott AxSYM is 
based on Microparticle Enzymes Immunoassay 
(MEIA) technique. 
11. Serum albumin was measured by Dimension RXL 
Max autoanalyzer instrument using bromocresol 
purple (BCP) dye-binding method. 
12. Patients’ recent-most blood/plasma/serum values of 
the afore-mentioned biochemical parameters were 
noted if already available provided they were done 
on the same day. 
13. Patients’ current medication details were noted. 
14. Patients’ demographic profile including age, sex was 
noted. 
Post data collection; patients were divided into two 
groups – CKD and Control. The serum levels of Ins, 
Cho, Tgl, HDL, LDL and plasma Glu between the two 
groups were compared for presence or absence of 
statistical significance. 
Homeostatic Model Assessment of Insulin Resistance 
(HOMA-IR) was calculated by the formula: 
HOMA-IR = Fasting Serum Insulin (µIU/mL) x Fasting 
Plasma Glucose (mg/dL) / 405 
Statistical Analysis: 
The statistical software Minitab 16 was used to analyze 
the data. Values of continuous and normally distributed 
variables were expressed as mean + standard deviation 
unless otherwise indicated, and differences in mean 
values between two groups were analysed using 
Student’s t-test. Descriptive information regarding 
categorical variable were presented as frequency. Test 
for equality of two proportions was used for comparison 
of categorical data. All tests were two tailed and 
considered statistically significant if p-value is < 0.05.  
RESULTS: 
Serum fasting Insulin level, HOMA-IR, serum hsCRP, 
serum urea, serum creatinine levels were significantly 
higher in ESRD patients compared to age and sex 
matched control individuals. Serum albumin level was 
significantly lower in ESRD patients compared to age 
and sex matched control individuals. (Refer Table 1)
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Table 1: Comparison of anthropological, demographic and biochemical statistics between CKD and control groups 
 Control ESRD p-value 
Sample size 95 97  
Male/Female 50/45 51/46 0.994 
Age 45.6 ± 9.2 47.3± 8.1 0.175 
BMI 25.2 ± 5.3 23.9 ± 7.2 0.155 
Fasting Plasma Glucose (mg/dL) 98 ± 22 103 ± 25 0.142 
Fasting Serum Insulin (µIU/mL) 8.2 ± 2.6 15.3 ±2.5 < 0.001* 
HOMA-IR 1.98 ± 0.14 3.89 ± 0.15 < 0.001* 
hsCRP (mg/L) 3.6 ± 1.8 7.6 ± 3.4 < 0.001* 
Triglyceride (mg/dL) 148 ± 45 158 ± 59 0.188 
Total Cholesterol (mg/dL) 176 ± 49 189 ± 45 0.057 
LDL (mg/dL) 87 ±  22 92 ±  26 0.152 
HDL (mg/dL) 42 ± 10.2 39 ± 9.8 0.039* 
Urea (mg/dL) 29 ± 9 69 ± 18 < 0.001* 
Creatinine (mg/dL) 0.9 ± 0.4 5.9 ± 1.1 < 0.001* 
Serum Albumin (g/dL) 4.5 ± 1.0 4.0 ± 1.2 0.002* 
* denotes statistical significance 
DISCUSSION: 
Our study confirms the association between ESRD and 
IR found in other studies8, 9, 10.  
Although the association between ESRD and IR has been 
established, the causality relation between them is not 
very clear. It is not yet clear whether ESRD causes IR in 
non-diabetic, non-hypertensive patients or IR leads to 
ESRD. Evidences supporting either direction of the 
causality relation have been found. 
IR has been known to be present even in early stages of 
CKD. Glucose Disposal Rate (GDR) in hyperinsulinemic 
euglycemic clamp test has been found to correlate 
negatively with plasma creatinine and positively with 
creatinine clearance rate4. Data from the Atherosclerosis 
Risk in Communities (ARICs) cohort confirmed a step-
wise increase in risk for ESRD development with the 
number of MetS criteria met in nondiabetic adults, ever 
after controlling for the development of diabetes mellitus 
(DM) and hypertension11. However, there is little 
evidence that preventing or treating symptoms of the 
MetS protects patients with renal impairment. 
IR, along with oxidative stress and inflammation, is 
suggested to play a role in the development of 
albuminuria and declining kidney function
12, 13
. IR 
promotes kidney disease by worsening renal 
hemodynamics through mechanisms such as activation 
of the sympathetic nervous system14, sodium retention, 
decreased Na+, K+-ATPase activity, and increased 
GFR13. Endoplasmic reticulum (ER) stress seems to be 
the factor-linking inflammation and IR at the molecular 
level. Renal ER stress is associated with proteinuria-
induced podocyte damage and alteration of nephrin N-
glycosylation in podocytes, which is the underlying 
factor in the pathogenesis of proteinuria, and is involved 
in the pathophysiology of chronic kidney injury with 
tubulointerstitial damage15. IR and inflammatory 
cytokine release may be partly responsible for 
glomerular mesangial expansion, basement membrane 
thickening, podocytopathy, and the loss of slit pore 
diaphragm integrity ultimately leading to 
glomerulosclerosis and tubulointerstitial injury16. 
Like other chronic diseases, patient with ESRD 
demonstrates low-grade systemic inflammation marked 
by elevated levels of proinflammatory cytokines17 such 
as C-reactive protein (CRP), tumor necrosis factor alpha 
(TNF-α), inerleukin-6 (IL-6), and interleukin-1 beta (IL-
1β). Inflammation and oxidative stress are evident in the 
early stage of CKD18 and are also known to induce IR, 
primarily via increased production of proinflammatory 
cytokines. 
There are evidences that the vitamin D and or 
parathyroid hormone (PTH) axis is important in the 
pathogenesis of glucose intolerance and IR in patients 
with ESRD. It has been found that IR is present in the 
early stages of ESRD and has an inverse association with 
25-hydroxyvitamin D levels19. The PTH level is usually 
elevated in ESRD patients. The mechanisms through 
which excess PTH blunts insulin sensitivity are 
uncertain. 
CONCLUSION: 
To the best of our knowledge, this is the first study in 
eastern India exploring the effect of ESRD on insulin 
resistance. Limitations of our study include a cross-
sectional design. In addition, results in this study may not 
be applicable to general population or to patients with 
hypertension in a primary care clinic because patients in 
an outpatient clinic in a hospital are selected patients. 
Conflict of interest: There was nothing to the best of 
our knowledge. 
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